Merck (MRK) Income from Non-Controlling Interests (2009 - 2026)

Merck (MRK) reported Income from Non-Controlling Interests of -$3.0 million for Q1 2026, down 150.0% year-over-year from $6.0 million in Q1 2025, and down 200.0% quarter-over-quarter from -$1.0 million in Q4 2025.

Merck (MRK) Income from Non-Controlling Interests (2009 - 2026) Analysis & Trends

Merck (MRK) has 18 years of Income from Non-Controlling Interests data on file, last reported at -$3.0 million in Q1 2026.

  • Income from Non-Controlling Interests for Q1 2026 came in at -$3.0 million, down 150.0% year-over-year; the trailing twelve-month figure through Mar 2026 was -$1.0 million (down 105.88% YoY), and the FY2025 annual result was $9.0 million, down 43.75% from the prior year.
  • Income from Non-Controlling Interests slipped to -$3.0 million in Q1 2026 per MRK's latest filing, from -$1.0 million in the prior quarter.
  • Over five years, Income from Non-Controlling Interests peaked at $6.0 million in Q2 2024 and troughed at -$3.0 million in Q1 2022.
  • A 5-year average of $2.6 million and a median of $3.5 million in 2023 frame the typical range for Income from Non-Controlling Interests.
  • The sharpest annual moves came in 2022 and 2025: Income from Non-Controlling Interests surged 400.0% in 2022, then plunged 200.0% in 2025.
  • A 5-year view of Income from Non-Controlling Interests shows it stood at $1.0 million in 2022, then surged by 400.0% to $5.0 million in 2023, then slumped by 80.0% to $1.0 million in 2024, then sank by 200.0% to -$1.0 million in 2025, then sank by 200.0% to -$3.0 million in 2026.
  • Business Quant data shows MRK's Income from Non-Controlling Interests at -$3.0 million in Q1 2026, -$1.0 million in Q4 2025, and $2.0 million in Q3 2025.

Peer Comparison

# Company Market Cap Enterprise Value Gross Profit (Qtr) Inc. Minority (Qtr)
1 Gsk 92,316,836.42 Bn 92,316,831.46 Bn 7.76 Bn 2.48 Bn
2 Eli Lilly 983.57 Bn 978.29 Bn 16.22 Bn -
3 Johnson & Johnson 553.56 Bn 531.50 Bn 15.96 Bn -
4 AbbVie 383.35 Bn 374.00 Bn 10.78 Bn 2.00 Mn
5 Merck 281.71 Bn 276.06 Bn 12.09 Bn -3.00 Mn
6 Amgen 182.20 Bn 170.16 Bn 5.87 Bn -
7 Gilead Sciences 153.71 Bn 145.98 Bn 5.52 Bn -
8 Pfizer 143.75 Bn 130.98 Bn -1.21 Bn 8.00 Mn
9 Bristol Myers Squibb 109.71 Bn 99.25 Bn 8.07 Bn 1.00 Mn
10 Novartis Ag 108.28 Bn 107.60 Bn - 415.00 Mn

Historic Data

Download Data
DateValue
Mar 31, 2026 -3.00 Mn
Dec 31, 2025 -1.00 Mn
Sep 30, 2025 2.00 Mn
Jun 30, 2025 1.00 Mn
Mar 31, 2025 6.00 Mn
Dec 31, 2024 1.00 Mn
Sep 30, 2024 4.00 Mn
Jun 30, 2024 6.00 Mn
Mar 31, 2024 5.00 Mn
Sep 30, 2023 5.00 Mn
Jun 30, 2023 3.00 Mn
Mar 31, 2023 4.00 Mn
Dec 31, 2022 1.00 Mn
Sep 30, 2022 5.00 Mn
Jun 30, 2022 5.00 Mn
Mar 31, 2022 -3.00 Mn
Dec 31, 2021 4.00 Mn
Sep 30, 2021 4.00 Mn
Jun 30, 2021 1.00 Mn
Mar 31, 2021 4.00 Mn